Search

Displaying results 6851 - 6860 of 10000 in total
  1. Drug

    Tigemocoxib

    go.drugbank.com/drugs/DB21699
    Experimental

    The usage of the INN stem '-coxib' in the name indicates that Tigemocoxib is a selective cyclo-oxygenase inhibitor. Tigemocoxib has a monoisotopic molecular weight of 334.06 Da.

  2. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

  3. Drug

    Tridolgosir

    go.drugbank.com/drugs/DB02034
    Experimental

    An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

  4. Drug

    Parasorbic acid

    go.drugbank.com/drugs/DB14121
    Investigational

    Sole constituent of "Vogelbeerol" oil obtained by steam distillation of the acidified juice of the ripe berries of the mountain ash.

  5. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  6. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today. … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

  7. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. … The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.

  8. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    ICA-105665 is a novel small molecule compound for the treatment of epilepsy. … It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy.

  9. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  10. Drug

    Rimtuzalcap

    go.drugbank.com/drugs/DB16733
    Investigational

    Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.[L38414]